COMBE FIVE (LIQUID)-TEN DOSE

Indications

• Whooping cough (pertussis)
• Respiratory tract infections caused by Bordetella species

Dosage

Adults: Refer to the B

Mechanism of action

Bordetella pertussis causes disease by adhering to the ciliated epithelial cells of the respiratory tract, leading to inflammation and disruption of normal respiratory function. The bacteria produce various virulence factors, including pertussis toxin, which interferes with host immune responses and causes systemic effects. The toxin primarily acts on the adenylate cyclase system, increasing cAMP levels, which disrupts cellular signaling pathways and contributes to the characteristic symptoms of whooping cough.

Pharmacodynamics

The symptoms of Bordetella infections, particularly whooping cough, are largely due to the host's immune response to the bacterial infection and the effects of the pertussis toxin. The disease progresses through stages, including the catarrhal stage (with mild symptoms), the paroxysmal stage (with severe coughing), and the convalescent stage (gradual recovery). Treatment may involve antibiotics to reduce the duration of symptoms and prevent transmission, although they do not significantly alter the course of the illness once the paroxysmal stage has begun.

Pharmacokinetics

As Bordetella is a bacterium, traditional pharmacokinetic parameters do not apply in the same way as for pharmaceuticals. The bacteria colonize the respiratory tract and can persist in the mucosal tissues, leading to prolonged symptoms. Antibiotics such as macrolides, which are commonly used to treat Bordetella infections, demonstrate variable absorption, distribution, metabolism, and excretion profiles depending on the specific drug used. For example, azithromycin has a long half-life and good tissue penetration.

Pregnancy

Bordetella pertussis vaccines are generally considered safe during pregnancy and are recommended to protect both the mother and the newborn from whooping cough.

Breast-feeding

The Bordetella pertussis vaccine can be administered during breastfeeding, as it is not known to pose a risk to nursing infants.

Storage

Store Bordetella pertussis vaccine in a refrigerator at temperatures between 2°C and 8°C. Do not freeze.

Formulations

• Bordetella pertussis vaccine (inactivated)
• Combination vaccines (e.g., DTaP - Diphtheria, Tetanus, and Pertussis)

Indications

• Diphtheria prevention through vaccination
• Management of diphtheria infections
• Treatment of complications arising from diphtheria toxin

Dosage

Children: Refer to established guidelines for the management of diphtheria in children. Treatment typically includes administration of diphtheria antitoxin and antibiotics.

Adults: Refer to established guidelines for the management of diphtheria. Treatment typically includes administration of diphtheria antitoxin and antibiotics.

Mechanism of action

Corynebacterium diphtheriae produces diphtheria toxin, which is a potent exotoxin that inhibits protein synthesis in host cells. The toxin binds to the heparin-binding epidermal growth factor (HB-EGF) receptor on cell membranes, facilitating its entry into cells. Once inside, it catalyzes the ADP-ribosylation of elongation factor-2 (EF-2), halting protein synthesis and leading to cell death.

Pharmacodynamics

The toxicity of diphtheria is primarily due to the action of its exotoxin. The severity of the disease is correlated with the amount of toxin produced, which can lead to local tissue necrosis in the throat, systemic effects such as myocarditis and neuropathy, and can be fatal if untreated. The immune response to the toxin plays a crucial role in recovery, as patients who have been previously vaccinated may exhibit milder disease due to pre-existing immunity.

Pharmacokinetics

The pharmacokinetics of diphtheria toxin involve its release into the bloodstream after local infections in the throat. The toxin can disseminate to various tissues, including the heart and nervous system, leading to systemic manifestations. The half-life of the toxin is not well established, but it is rapidly cleared from circulation following the development of antibodies in the host, which neutralize the toxin's effects.

Adverse effects

• Local reactions at the injection site
• Fever
• Fatigue
• Allergic reactions
• Anaphylaxis (rare)

Precautions

• History of severe allergic reactions to diphtheria toxoid or any component of the vaccine
• Use with caution in individuals with immunocompromised conditions

Pregnancy

Diphtheria vaccination is generally considered safe during pregnancy and is recommended to protect both the mother and fetus from potential exposure.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding and is recommended as it helps to protect the infant.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine (inactivated)
• Diphtheria-tetanus-pertussis (DTP) combination vaccine

Indications

• Pneumonia caused by Haemophilus influenzae
• Meningitis caused by Haemophilus influenzae
• Epiglottitis caused by Haemophilus influenzae
• Otitis media
• Sinusitis

Dosage

Children: Refer to specific antibiotic guidelines for dosing in paediatric patients, as it varies by drug and infection severity.

Adults: Refer to specific antibiotic guidelines for dosing in adult patients, as it varies by drug and infection severity.

Mechanism of action

Haemophilus influenzae infections are treated with antibiotics that target bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis. Commonly used antibiotics include beta-lactams, which inhibit the enzyme transpeptidase involved in cross-linking peptidoglycan layers in the bacterial cell wall, leading to cell lysis and death.

Pharmacodynamics

The pharmacodynamics of antibiotics used against Haemophilus influenzae depend on their mechanism of action. Beta-lactams exhibit time-dependent killing, where the efficacy is related to the duration of time the drug concentration remains above the minimum inhibitory concentration (MIC). Other antibiotics may have concentration-dependent effects, where higher drug concentrations achieve a more significant bactericidal effect.

Pharmacokinetics

The pharmacokinetics of antibiotics varies by specific drug class. Generally, beta-lactams are well absorbed orally, with distribution into body tissues and fluids. They are primarily excreted unchanged in the urine. The half-life can vary, affecting dosing frequency. Other classes, such as macrolides, may have different absorption and excretion profiles, impacting their clinical use.

Pregnancy

The use of Haemophilus vaccines during pregnancy should be considered based on the potential benefits and risks, particularly in populations with a high incidence of disease.

Breast-feeding

Breastfeeding is generally considered safe while receiving Haemophilus vaccines, as the benefits outweigh potential risks.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Indications

• Acute viral hepatitis
• Chronic hepatitis B
• Chronic hepatitis C
• Autoimmune hepatitis
• Alcoholic hepatitis
• Non-alcoholic fatty liver disease

Dosage

Children: Paediatric dosing also varies significantly based on the specific condition and medication. As with adult dosing, it is important to refer to the BNF for Children for specific recommendations.

Adults: Dosing for adult patients varies widely depending on the specific antiviral agent used and the type of hepatitis. It is essential to refer to specific guidelines or the BNF for precise dosing.

Mechanism of action

In viral hepatitis, the viruses typically enter liver cells and replicate, leading to cellular injury and inflammation. The immune response to the infection contributes to liver damage. Antiviral therapies aim to inhibit viral replication, either by directly targeting viral enzymes or by modulating the host immune response.

Pharmacodynamics

The pharmacodynamics of antiviral agents used in hepatitis treatment involve the inhibition of viral replication, reduction of viral load, and improvement of liver function. This can lead to a decrease in serum liver enzymes (ALT and AST) and an improvement in clinical symptoms. In chronic hepatitis B and C, sustained virologic response is the goal, indicating effective viral suppression.

Pharmacokinetics

The pharmacokinetics of antiviral medications used for hepatitis can vary significantly depending on the specific drug. Generally, these agents are absorbed from the gastrointestinal tract, metabolized in the liver, and excreted through urine or feces. The half-lives of these drugs can vary, influencing dosing schedules.

Pregnancy

Consult medical guidelines as hepatitis can pose risks during pregnancy; specific management depends on the type of hepatitis.

Breast-feeding

Consult healthcare providers, as the safety of certain hepatitis medications during breastfeeding varies.

Storage

Store in a cool, dry place away from direct sunlight; specific storage conditions may vary based on the medication used.

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid